High levels of CTGF expression correlate positively with glioblastoma growth (57), invasive melanoma behavior (58), poor prognosis in esophageal adenocarcinoma (59), aggressive behavior of pancreatic cancer cells (60), and bone metastasis in breast cancer (61). This evidence concerns the gene CCN2 and breast carcinoma.